The U.K. now classifies cannabidiol as medication. This post from Mixmag News discusses how the legalization of CBD may lead to profound medical research.
The Medicines & Healthcare products Regulatory Agency, also known as a MHRA, has publicly classified cannabidiol, or CBD, as medication in the UK.
The legalisation of the marijuana derivative is a result of well-documented research, citing its medical benefits for treatment of serious medical illnesses. CBD has been proven to effectively alleviate severe symptoms like seizures and combat neurodegenerative and psychosis disorders, tumors and cancer-related ailments.
MHRA Director of Inspection and Enforcement, Gerald Heddel, explained that cannabidiol as a medicinal ingredient will properly regulate its production and use, and allow for further research on the substance. The decision arrived in light of the incredible advancements and heightened quality of life CBD had given many patients.
The big change is a stark comparison to current adjustments in the US, where cannabidiol is classified as a Schedule 1 drug alongside heroin, LSD and marijuana, falling under the category of having “no medical use with high potential for abuse”.
Although CBD is specifically now labeled as medication in the UK, marijuana and cannabis is still criminalized under federal law.